Effect of riboflavin treatment on human red cell pyruvate kinase deficiency.
The effect of riboflavin on six patients with hemolytic anemia due to hereditary pyruvate kinase deficiency was studied. Treatment over a period of four to six months produced no significant hematologic or enzymologic changes in the variants investigated.
D000746:Anemia, Hemolytic, Congenital Nonspherocytic / Q000188:drug therapy; D004912:Erythrocytes / Q000201:enzymology*; D005980:Glutathione Reductase / Q000378:metabolism; D006801:Humans; D011770:Pyruvate Kinase / Q000097:blood / Q000172:deficiency*; D012256:Riboflavin / Q000627:therapeutic use*
D005980:Glutathione Reductase; D011770:Pyruvate Kinase; D012256:Riboflavin